Cofoe Medical Technology (301087) Q1 2026 earnings summary

Executive summary

• Q1 revenue rose 37.22% YoY to ¥1,012,368,240.57; net profit attributable to shareholders increased 17.08% to ¥107,041,703.68.

• Growth was driven by higher sales across core medical and health categories and stronger online channels, alongside increased marketing costs.

Financial highlights

• Revenue was ¥1,012,368,240.57, up 37.22% YoY; operating profit was ¥128,666,168.48 versus ¥109,667,821.89 in the prior-year quarter.

• Net profit attributable to shareholders was ¥107,041,703.68, up 17.08% YoY; adjusted for non-recurring items, net profit was ¥93,790,509.89, up 36.88%.

• Operating cash flow was ¥102,560,132.89, down 6.81% YoY; total assets were ¥6,913,387,005.28, up 4.29% from year-end.

• Sales costs rose 54.50% YoY to ¥352,910,826.12 as online business expanded and marketing investment increased.

Segment performance

• Core medical and health categories recorded a substantial increase in sales, with growth across multiple categories and strong online-channel contribution.